Abstract:Cervical cancer is one of the malignant tumors that gravely endangers women's health, and it is notably the only malignant tumor that can be eradicated through targeted tertiary screening measures. [ 1 ] The process from high-risk human papillomavirus infection to the natural progression towards cervical cancer spans several decades. [ 2 ] Human papillomavirus (HPV) infections are particularly prevalent in young women, especially those around the age of 20. The prevalence of HPV decreases significantly after the age of 25 to 30. However, a subsequent increase is observed in women between the ages of 50 and 60, most of whom are either perimenopausal or postmenopausal. [ 3 ] Factors such as previous cervical screenings or the experience of becoming widowed may lead these women to mistakenly perceive themselves as being at a lower risk. This misperception tends to reduce their engagement in regular screening and lowers their awareness of potential diseases, subsequently increasing the incidence of cervical cancer. [ 3 ] High-grade squamous intraepithelial lesions (HSIL) are detectable during cervical cancer screenings, and effectively treating HSIL can significantly reduce the incidence of cervical cancer. [ 4 ] HSIL may naturally progress through 3 potential outcomes: regression, persistence, or progression. Importantly, HSIL carries an increased risk of developing into cervical cancer. Modeling studies indicate that untreated HSIL will evolve into invasive cancer in 15% to 23% of cases within an average of 13 years, with lifetime risk escalating to 40%. [ 5 ] Moreover, postmenopausal women experience a reduction in estrogen levels, cervical atrophy, an inward shift of the squamous-columnar junction, and decreased sexual activity, all of which contribute to the absence of pronounced clinical symptoms and signs in the early stages, thus complicating the detection of cervical lesions in clinical settings. [ 6 ] Furthermore, postmenopausal women often exhibit low cancer prevention awareness, conservative attitudes, and face economic constraints, which diminish their engagement in cervical screening. Their hesitance to seek prompt medical care, even after noticing abnormalities, typically results in delayed detection of cervical lesions in this demographic. In some instances, cervical cancer is detected at mid-to-late stages of invasion, leading to a poor prognosis and high mortality rates, which severely impact the physical and mental health of postmenopausal women. [ 6 ] Additionally, the physiological characteristics of postmenopausal women differ markedly from those of sexually mature women due to atrophy of the lower genital tract, difficulty in fully exposing the cervical transformation zone, and thinning of the cervical epithelium, complicating the diagnosis and treatment of HSIL. [ 7 ] This study discusses the clinical characteristics of postmenopausal women with HSIL and analyzes the postoperative pathological outcomes following various surgical interventions. The findings aim to provide appropriate recommendations for screening cervical lesions and selecting the optimal surgical approach for HSIL in postmenopausal women.

Thin variant of high-grade squamous intraepithelial lesion - relationship with high-risk and possibly carcinogenic human papilloma virus subtypes and somatic cancer gene mutations

Cervical Precancers Originate From Infected Proliferating Reserve Cells

Use of High-Risk Human Papiilomavirus DNA Testing to Deal with Atypical Squamous Cells-Can-not Exclude HSIL

Underdiagnosis of Cervical Intraepithelial Neoplasia by Colposcopy and Its Association with Thin High‑grade Squamous Intraepithelial Lesions.

A Retrospective Analysis on 1901 Women with High Grade Cervical Intraepithelial Neoplasia by Colposcopic Biopsy.

Incidence of cervical high-grade squamous intraepithelial lesions and squamous cell carcinoma in women with high-risk human papilloma virus and normal cervical cytology: A retrospective analysis of 1858 cases stratified by age and HPV genotype.

The Histologic and Molecular Spectrum of Highly Differentiated HPV-independent Cervical Intraepithelial Neoplasia

Performance of Human Papillomavirus (HPV) 16 and 18/45 Genotyping Combined with Age Stratification in the Triaging of Women with Histologic Low-Grade Squamous Intraepithelial Lesions Preceded by HPV Oncogenic Mrna-Positive/normal or Mildly Abnormal Cytology: A Longitudinal Study

Analysis of the clinical characteristics and surgical methods of high-grade squamous intraepithelial lesions of the cervix in postmenopausal women: A retrospective case study

Immunohistochemistry and in situ hybridization for the diagnosis and classification of squamous lesions of the anogenital region

Low methylation marker levels among human papillomavirus‐vaccinated women with cervical high‐grade squamous intraepithelial lesions

Cmar_a_328279 6869..6877

Distribution of cervical lesions in high-risk HPV (hr-HPV) positive women with ASC-US: a retrospective single-center study in China

Human papillomavirus genotyping for predicting disease progression in women with biopsy-negative or cervical intraepithelial neoplasia grade 1 of low-grade intraepithelial lesion cytology

Significance of high-risk human papillomavirus DNA-positive atypical squamous cells of undetermined significance pap smears in perimenopausal and postmenopausal women

Visual appearance of the uterine cervix differs on the basis of HPV type status in high-grade squamous intraepithelial lesion: the results of a reliable method

[Characteristics of Invisible Cervical Intraepithelial Neoplasia Ⅲ under Colposcopy].

Prevalence of Cervical Precancers or Cancers in Women with ASC-H/HSIL Cytology According to Aptima HPV (AHPV) Assay-Detected HPV Genotypes and Age.

Application of Liquid Based Cytology and High-risk Human Papillomavirus DNA Test for the Screening Cervical Lesions

Risk factors associated with HPV persistence after conization in high-grade squamous intraepithelial lesion

High‐grade squamous intraepithelial lesions and adenocarcinoma in situ with a negative HPV cervical screening test. The role of HPV‐ISH testing: A retrospective review